Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Camilo Gonima

Obstetrics & Gynecology San Antonio, TX Medical Doctor

NPI 1316964745 CMS profile 241210

7940 Floyd Curl Dr, Suite 900, San Antonio, TX 78229

Open in the dashboard

General payments

$203,361

472 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$2

2 holdings reported · through program year 2025

Through program year 2025, Camilo Gonima of San Antonio, TX is reported in the CMS Open Payments database as having received $203,361 across 472 general payments and $0 in research payments paid to them. They also declared ownership or investment interests valued at $2 across 2 holdings.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Obstetrics & Gynecology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

9 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $33,655 58
2024 General $29,829 52
2023 General $41,629 65
2022 General $42,793 91
2021 General $31,525 97
2020 General $12,219 57
2019 General $11,711 52
2024 Ownership $1 1
2023 Ownership $1 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Camilo Gonima
  • Obstetrics & Gynecology median
  • Middle half of Obstetrics & Gynecology
  • National median

In program year 2025, general payments to Camilo Gonima were reported at $33,655. Among 21,306 Obstetrics & Gynecology profiles paid that year, the median was $158 and the middle half received between $51 and $401.

Show as a table
Year Camilo Gonima Obstetrics & Gynecology median Middle half National median
2019 $11,711 $172 $62–$391 $163
2020 $12,219 $94 $36–$222 $114
2021 $31,525 $136 $42–$369 $132
2022 $42,793 $160 $50–$433 $149
2023 $41,629 $169 $56–$423 $160
2024 $29,829 $152 $50–$371 $164
2025 $33,655 $158 $51–$401 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Organon LLC $164,760 156 payments
  2. Merck Sharp & Dohme Corporation $33,406 52 payments
  3. AbbVie, Inc. $1,567 74 payments
  4. Daiichi Sankyo Inc. $787 41 payments
  5. Mayne Pharma Inc. $453 20 payments
  6. Astellas Pharma US Inc $340 16 payments
  7. Exeltis, USA Inc. $261 15 payments
  8. Biogen, Inc. $204 10 payments
  9. Agile Therapeutics, Inc. $166 11 payments
  10. Pacira Pharmaceuticals Incorporated $147 3 payments
  11. Other $1,269 74 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for serving as faculty or as a speaker for a medical education program $144,084 97 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $52,375 40 payments
  3. Food and Beverage $6,817 334 payments
  4. Education $85 1 payment
Products named General payments · program years 2019–2025
  1. NEXPLANON Etonogestrel $134,860 129 payments
  2. NEXPLANON Womens Health $33,380 50 payments
  3. Nexplanon Womens Health $19,391 14 payments
  4. LO LOESTRIN FE $810 38 payments
  5. ORILISSA $700 33 payments
  6. INJECTAFER Iron Deficiency Anemia $435 21 payments
  7. ORIAHNN $403 19 payments
  8. INJECTAFER Anemia $353 20 payments
  9. SLYND $228 13 payments
  10. Veozah $193 11 payments
  11. Other $2,216 126 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 4 drugs

Part D claims

64

Median for Obstetrics & Gynecology: 65

Drug cost

$1,839

Median for Obstetrics & Gynecology: $3,585

Branded share of claims

21.9%

Median for Obstetrics & Gynecology: 25.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Estradiol Generic 23 $656
Solifenacin Succinate Generic 14 $529
Medroxyprogesterone Acetate Generic 13 $471
Oxybutynin Chloride Er Oxybutynin Chloride Brand 14 $183

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 24,311 Part D prescribers listed as Obstetrics & Gynecology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 14 billing codes

Paid by Medicare

$4,002

Medicare's payments for the services billed

Medicare patients

30

Average age 67

Services billed

76

30 women, 0 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 50%
Arthritis 40%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

4 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Veozah
  • Astellas Pharma US Inc $83
$83 — —
INJECTAFER
  • Daiichi Sankyo Inc. $54
$54 — —
Exparel
  • Pacira Pharmaceuticals Incorporated $21
$21 — —
MYFEMBREE
  • Sumitomo Pharma America, Inc. $16
$16 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

472 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Obstetrics & Gynecology in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record